Vitiligo Treatment Market Analysis, Trends And Forecast Outlook 2024-2033

The vitiligo treatment market size has grown strongly in recent years. It will grow from $1.49 billion in 2023 to $1.59 billion in 2024 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to increased prevalence of vitiligo, advancements in dermatology research, improving patient awareness, diverse treatment modalities, patient-centric approach in healthcare.

The vitiligo treatment market size is expected to see strong growth in the next few years. It will grow to $2 billion in 2028 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to innovations in immunomodulatory therapies, increasing research funding, global health initiatives for dermatological conditions, growing acceptance of combination therapies, enhanced dermatology care infrastructure. Major trends in the forecast period include combination therapies, research and development, patient-centric approaches, global awareness and advocacy, regulatory landscape.

Market Overview -
Vitiligo treatment refers to a treatment of a chronic autoimmune condition that causes pigmentation or color loss in regions of the skin. Vitiligo treatments are helpful in halting and reversing the progression.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=10843&type=smp

The Rise In Healthcare Expenditure
The rise in healthcare expenditure is expected to propel the growth of the vitiligo treatment market going forward. Healthcare expenditure refers to an expense that covers all costs associated with providing health services, family planning, nutrition, and emergency help with a focus on health. Improved healthcare expenditure will aid in providing better treatment to all patients suffering from vitiligo. Additionally, effective primary healthcare will promote population health through the integration of primary care services with public health. For instance, in March 2022, according to the 2021-2030 National Health Expenditure (NHE) report published by the Centers for Medicare & Medicaid Services, a US-based Department of Health and Human Services department, the annual increase in national health spending was predicted to average 5.1% between 2021 and 2030, reaching approximately $6.8 trillion by 2030. Additionally, throughout the period 2021-2030, Medicare expenditures are expected to expand at a 7.2% annual rate, while Medicaid spending is expected to grow at a 5.6% annual rate. Therefore, the rise in healthcare expenditure is driving the growth of the vitiligo treatment market.

Competitive Landscape -
Major companies operating in the vitiligo treatment market report are Cliniuvel Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., Pfizer Inc., Incyte Corporation, STRATA Skin Sciences, Astellas Pharma Inc., Bausch Health Companies Inc., Arcutis Biotherapeutics, Strides Pharma Science Limited, Mylan N.V., Glenmark Pharmaceuticals Ltd., Clarify Medical Inc., Novartis AG, LEO Pharma A/S, Dermfix Ltd, Bristol-Myers Squibb, Dermavant Science Inc., Merck KGaA, Celgene, Boston Pharmaceuticals, DermTech, Galderma S.A., Allergan Inc., Amgen, Koninklijke Philips N.V., Sun Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., Vitiligo Research Foundation, Vitiligo Bond Inc., Vitiligo Society, Vitiligo Clinic and Research Center, Vitiligo Support International

Fda Authorization Of Opzeluratm Cream Marks A Milestone In Innovations For Non-Segmental Vitiligo Treatment
Product innovations are a key trend gaining popularity in the vitiligo treatment market. Companies operating in the vitiligo treatment market are focused on introducing new products to sustain their position in the market. For instance, in July 2022, Incyte Corporation, a US-based pharmaceutical firm, announced that the FDA has authorized OpzeluraTM (ruxolitinib) cream 1.5% for the topical treatment of non-segmental vitiligo in adult and pediatric patients 12 years of age and older. Opzelura is licensed for continued topical application twice daily to afflicted regions of up to 10% of the body surface area in individuals with non-segmental vitiligo. Patients who received Opzelura at Week 24 showed a consistent 75% improvement from baseline in the face Vitiligo Area Scoring Index (F-VASI75).

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/vitiligo-treatment-global-market-report

Key Segments -
The vitiligo treatment market covered in this report is segmented -
1) By Drugs: Antihistamines, H2 Antagonists, Tricyclic Antidepressants, Other Drugs
2) By Types: Acute Urticaria, Chronic Urticaria
3) By Mode Of Administration: Injectable, Oral, Other Modes Of Administration
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.